Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network

Montgomery, LaTrice; Winhusen, Theresa; Scodes, Jennifer; Pavlicová, Martina; Twitty, Dylanne; Campbell, Aimee N.C.; Wang, An Li; Nunes, Edward V.; Rotrosen, John

doi:10.1016/j.jsat.2021.108489

Cited by 6 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interaction between smoking and opioid medications presents a complex dynamic. While buprenorphine did not worsen smoking, it was less effective than naltrexone in reducing smoking behavior 36 . This highlights the importance of tailored treatment approaches for concurrent opioid and nicotine dependence.…”

Section: Discussionmentioning

confidence: 82%

Impact of the Ottawa model on opiate screening and smoking cessation in methadone-treated patients with opioid use disorder: A retrospective cohort analysis

Lee,

Yu,

Yen

et al. 2024

Tob. Induc. Dis.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 82%

Impact of the Ottawa model on opiate screening and smoking cessation in methadone-treated patients with opioid use disorder: A retrospective cohort analysis

Lee,

Yu,

Yen

et al. 2024

Tob. Induc. Dis.

View full text Add to dashboard Cite

“…The pro-smoking social norms, social networks composed of predominantly smokers, psychological distress, perceived stress and intolerance of withdrawal discomfort have been identified as some of the challenges facing opioid-dependent patients wanting to quit smoking ( 16 ). In addition, growing evidence indicate that interactions between nicotine and OAT medication increase smoking ( 16 , 19 – 21 ); providing a possible explanation for the low quit rates among patients receiving OAT. Further, patients receiving OAT are rarely offered smoking cessation interventions ( 22 , 23 ).…”

Section: Introductionmentioning

confidence: 99%

A qualitative study on people with opioid use disorders’ perspectives on smoking and smoking cessation interventions

et al. 2023

View full text Add to dashboard Cite

IntroductionSmoking-related diseases are major contributors to disability and shorter life expectancy among opioid-dependent patients. Smoking prevalence is considerably higher for opioid-dependent persons than among the general population, and only a minority quit smoking in treatment settings. Studies show that pharmacological smoking cessation interventions have modest success rates. This study aimed to investigate patients’ receiving opioid agonist therapy perspectives on factors affecting behavior and decisions related to smoking cessation, and their experiences with smoking cessation.MethodsThis is a qualitative study using semi-structured individual interviews. The participants were asked, among others, to elaborate on the participants’ thoughts about smoking, previous attempts to quit tobacco use, and what could prompt a smoking cessation attempt. We analyzed the transcripts with systematic text condensation. The Standards for Reporting Qualitative Research and the Consolidated Criteria for Reporting Qualitative Research guidelines were followed. Opioid-dependent patients receiving opioid agonist therapy in outpatient clinics were invited to participate using a purposive sampling method. In total, fourteen individuals participated in this study.ResultsWe identified six themes which were: (1) reflections on how smoking affected decisions, (2) smoking and its impact on physical and mental health, (3) the economy as a motivator to stop smoking, (4) emotions, desires, and habits related to smoking, (5) knowledge of smoking, smoking cessation, and quit attempts, and (6) social factors influencing the participants’ choices and activities. The participants were well informed about the consequences of smoking and had some knowledge and experience in quitting. The participants’ pulmonary health was an important motivational factor for change. Withdrawal symptoms, anxiety, and fear of using other substances discouraged several from attempting to quit smoking. In contrast, social support from partners and access to meaningful activities were considered important factors for success. Few reported being offered help from health professionals to make a smoking cessation attempt.DiscussionExperiencing social support, being encouraged to quit smoking, and patients’ concerns for their physical health were important reasons for wanting to quit smoking. Smoking cessation interventions based on patient preferences and on the behavior change wheel may enable a higher success rate among patients receiving opioid agonist therapy.

show abstract

Opioid agonist treatment for people who are dependent on pharmaceutical opioids

Nielsen

Tse

Larance

2022

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network

Cited by 6 publications

References 39 publications

Impact of the Ottawa model on opiate screening and smoking cessation in methadone-treated patients with opioid use disorder: A retrospective cohort analysis

Impact of the Ottawa model on opiate screening and smoking cessation in methadone-treated patients with opioid use disorder: A retrospective cohort analysis

A qualitative study on people with opioid use disorders’ perspectives on smoking and smoking cessation interventions

Opioid agonist treatment for people who are dependent on pharmaceutical opioids

Contact Info

Product

Resources

About